Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

NeuroStar® Launches Largest Depression Outcomes Registry to Date

NeuroStar Advanced Therapy
Posted on: 21 Nov 16

PR Newswire

MALVERN, Pa., Nov. 21, 2016

MALVERN, Pa., Nov. 21, 2016 /PRNewswire/ -- NeuroStar announced today the launch of the largest depression outcomes registry ever in patients treated with its TMS (transcranial magnetic stimulation) therapy. The new outcomes registry is expected to exceed the total number of patients reported in STAR*D, which was the first federally funded, large-scale, long-term study directly comparing treatment strategies for patients with depression.

"In the long term, the research obtained from this registry has the potential to change the way we provide care to people with chronic depression," said Kenneth P. Pages, M.D., Medical Director, TMS of South Tampa. "The information collected over the years will equip physicians with case histories and the necessary research to tailor the most effective treatment plans. This, in turn, will allow us to better understand and ultimately meet the needs of these patients."

The outcomes registry was established for the collection and analysis of data from patients with Major Depressive Disorder (MDD) who have been treated with NeuroStar Advanced Therapy. The intent of the registry is to further investigate and better understand the use of the therapy in a clinical setting. As such, data is expected to be collected from more than 6,000 depression patients across at least 100 different treatment facilities in the United States.

"There are currently more than 740 NeuroStar providers across the U.S., with over one million treatments delivered to-date," said Mark Demitrack, MD, Chief Medical Officer for NeuroStar. "We are thrilled to roll out this registry to participating physicians and are striving for it to become the largest depression patient database ever.  The primary objective of the multi-site, observational dataset is to report disease state outcomes for MDD patients treated with NeuroStar Advanced Therapy using validated clinical rating scales, thus enabling better patient care through easy, efficient outcomes analysis."

NeuroStar is the leader in peer reviewed research, with 23 publications supporting the efficacy, safety, and durability of NeuroStar transcranial magnetic stimulation. In open-label clinical trials, 58% of people treated significantly responded, with 37% achieving complete remission of their depression symptoms.1 Among people followed for 12 months after acute treatment, 68% retained their response.2

About NeuroStar Advanced Therapy
NeuroStar is the established leader in transcranial magnetic stimulation (TMS) therapy, a non-invasive form of neuromodulation. It is backed by the largest clinical data set for MDD of any TMS Therapy.  NeuroStar is the #1 physician-preferred TMS treatment for patients with MDD.

With over 300 million covered lives, NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.

Insurance coverage information is available at

NeuroStar is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05).[3]

The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head. Long term durability of effect has not been established in a randomized controlled trial.

For full safety and prescribing information, visit

Availability of NeuroStar Advanced Therapy
Treatment with NeuroStar Advanced Therapy is available at more than 740 treatment centers in 49 states. More information on specific treatment locations that offer NeuroStar Advanced Therapy is available at: or by calling NeuroStar Customer Service at 877-600-7555.

For more information, please visit

NeuroStar®, NeuroStar TMS Therapy® and TMS Therapy® are registered trademarks of Neuronetics, Inc.

Media Contact:
Melissa Maycott
Tonic Life Communications
Office: 215-928-2192
Cell: 215-584-8782

1Carpenter LL, et al. Depress Anxiety, (2012)
2Dunner, DL, et al. J Clin Psych, (2014)
3George MS, et al. Arch Gen Psychiat, (2010)

Logo -

To view the original version on PR Newswire, visit:

SOURCE NeuroStar Advanced Therapy

PR Newswire

Last updated on: 21/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.